The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1279
February 11, 2008
View Complete Issue         Table of Contents 2019 
Budesonide/Formoterol (Symbicort) for Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Budesonide/Formoterol (Symbicort) for Asthma
February 11, 2008 (Issue: 1279)
A combination of the corticosteroid budesonide and the long-acting beta2-agonist formoterol (Symbicort - AstraZeneca) has become available in a metered dose inhaler for long-term maintenance treatment of asthma in patients ≥ 12 years old. A...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Budesonide/Formoterol (Symbicort) for Asthma
Article code: 1279a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.